Aculife Healthcare Private Limited

Aculife Healthcare Private Limited, established on July 28, 2014, is a private pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24233GJ2014PTC080271. As of March 31, 2025, Aculife reported an authorized capital of ₹600.00 crore and a paid-up capital of ₹431.48 crore. The company employs approximately 2,880 professionals, reflecting its significant presence in the pharmaceutical manufacturing sector.

Aculife specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its product portfolio spans six products across four therapeutic categories, with a notable concentration in advanced antibiotics and cardiovascular medications. The company's registered office is located at Commerce House - V, Besides Vodafone House, Prahladnagar Corporate Road, Ahmedabad, Gujarat, 380051, India.

Aculife Healthcare operates manufacturing facilities in Ahmedabad, Gujarat, India. While specific details regarding plant locations and capacities are not publicly disclosed, the company's substantial workforce and product portfolio suggest well-equipped facilities capable of producing a diverse range of pharmaceutical formulations. The focus on advanced antibiotics and cardiovascular products indicates specialized manufacturing capabilities in these therapeutic areas.

The leadership team at Aculife Healthcare includes:

• Guhaprasad Nagarajan: Chief Executive Officer (CEO), appointed on November 29, 2023.

• Amar Narendrabhai Shah: Whole-Time Director, serving since May 23, 2017.

• Ajay Bhushanlal Khushu: Director, with tenure since July 28, 2014.

• Paresh Balmukund Sheth: Director, also serving since July 28, 2014.

These leaders bring extensive experience to the company, guiding its strategic direction and operational execution.

Aculife Healthcare's export activities, as reported by TransData Nexus, include shipments to various international markets. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's focus on advanced antibiotics and cardiovascular products suggests potential interest in these regulated markets, where such therapeutics are in demand. Further information would require direct engagement with regulatory bodies or the company itself.

Aculife Healthcare's export data indicates shipments to emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's product portfolio, particularly in advanced antibiotics and cardiovascular medications, aligns with the healthcare needs in these regions. While specific details on WHO prequalification or other certifications enabling access to these markets are not publicly disclosed, the company's export activities suggest a strategic focus on expanding its presence in emerging markets.

Aculife Healthcare's export data reveals a concentration in a limited number of products, with the top five accounting for 98.4% of total export value. This indicates a focused product strategy, potentially reducing diversification and increasing concentration risk. The company's strategic direction appears to emphasize high-demand therapeutic areas, such as advanced antibiotics and cardiovascular products, which may guide its geographic expansion and market penetration efforts.

Specific details regarding Aculife Healthcare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data suggests a focus on markets where such regulatory approvals are essential. For comprehensive information, direct engagement with the FDA or the company is recommended.

Information regarding Aculife Healthcare's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. Given the company's export activities, obtaining these certifications would be advantageous for accessing international markets. Prospective partners should verify the company's compliance with these standards through direct communication.

Aculife Healthcare holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has approvals from state drug controllers, as indicated by its active status and compliance with Indian regulatory requirements. The company's export activities suggest it possesses the necessary export No Objection Certificates (NOCs) for international shipments. For detailed verification, consulting the CDSCO or the company directly is advisable.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Aculife Healthcare. The company's active status and compliance with regulatory requirements suggest a favorable regulatory standing. For the most current information, direct engagement with regulatory bodies or the company is recommended.

Aculife Healthcare operates in the competitive pharmaceutical manufacturing sector, focusing on advanced antibiotics and cardiovascular products. While specific competitors are not identified in the available data, the company's product portfolio positions it in direct competition with other manufacturers specializing in these therapeutic areas. Market share comparisons and head-to-head analyses would require access to detailed industry reports and competitor data.

Aculife Healthcare's focus on high-demand therapeutic areas, such as advanced antibiotics and cardiovascular medications, distinguishes it in the pharmaceutical manufacturing sector. The company's substantial export activities and product portfolio reflect its commitment to addressing global healthcare needs. Further insights into its unique strengths and competitive advantages would require direct engagement with the company.

Aculife Healthcare's strategic direction appears to emphasize the production of high-demand pharmaceutical formulations, particularly in advanced antibiotics and cardiovascular products. The company's export activities suggest a focus on expanding its presence in both regulated and emerging markets. Future outlooks would depend on market dynamics, regulatory developments, and the company's ability to adapt to evolving healthcare needs.

Aculife Healthcare's substantial export volume and product portfolio indicate a reliable track record in pharmaceutical manufacturing. The company's focus on high-demand therapeutic areas suggests consistency in meeting market needs. Reliability indicators, such as on-time delivery and product quality, would require direct feedback from customers and partners.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Facility Registration: Confirm the company's registration status with the FDA.

• WHO-GMP Certification: Verify compliance with World Health Organization Good Manufacturing Practices.

• EU GMP Certification: Ensure adherence to European Union Good Manufacturing Practices.

• ISO Certification: Check for relevant International Organization for Standardization certifications.

Verification can be conducted through direct communication with the company or by consulting the respective regulatory bodies.

Prospective partners should undertake the following steps to ensure a thorough evaluation:

• Verify Regulatory Compliance: Confirm certifications and approvals from relevant authorities.

• Assess Financial Health: Review financial statements and credit reports.

• Evaluate Product Quality: Request product samples and quality assurance documentation.

• Check References: Obtain feedback from current or previous partners.

• Inspect Manufacturing Facilities: Conduct site visits to assess operational standards.

Red flags to watch for include inconsistent financial records, lack of transparency in operations, and unresolved regulatory issues. Pre-order checks should include verifying product specifications, lead times, and after-sales support.